DefEYE Announces Publication of Multiple Peer-Reviewed Articles Highlighting Use of Biovance 3L Ocular
Sarasota, FL – February 23, 2026 – DefEYE, Inc, a privately held ophthalmics company focused on innovative placental-based biologic solutions for ocular surface disease and surgical applications, today announced the publication of two peer-reviewed articles highlighting the use of Biovance 3L Ocular, the only tri-layer decellularized basement membrane (DBM) in ocular surgery and in ocular […]